Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse
NCT00677716 · View on ClinicalTrials.gov ↗
Study Summary
Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus literally destroys the tumor "from the inside out". This may be an effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
Conditions Studied
Interventions
- DRUG 131I-chTNT-1/B MAb (Cotara)
Study Locations (7)
Other
- Manipal Institute for Neurological Disorders, — Bangalore
- Department of Neurosurgery Jaslok Hospital and Research Centre — Mumbai
- All India Instutite of Medical Sciences — New Delhi
Arizona
- Barrow Neurological Institute — Phoenix
Pennsylvania
- University of Pennsylvania, Department of Neurosurgery — Philadelphia
South Carolina
- Medical University of South Carolina — Charleston
Kerala
- Amrita Institute of Medical Sciences and Research Center, — Kochi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00677716
The ClinicalTrials.gov registry entry for NCT00677716 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Glioblastoma Multiforme appearing as the primary indexed condition, and to 1 intervention — of which 131I-chTNT-1/B MAb (Cotara) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00677716 reports 7 study locations spanning 5 distinct geographic areas — top geographies include Other, Arizona, Pennsylvania. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00677716 about?
NCT00677716 is a clinical study titled "Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse". Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and deliver radiation directly to the center of the tumor mass while minimizing effects on normal tissues. Cotara® thus l...
What is the current status of trial NCT00677716?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-07. Estimated completion is 2011-11.
What conditions does trial NCT00677716 study?
This clinical trial studies the following conditions: Glioblastoma Multiforme. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00677716?
The interventions under investigation include: 131I-chTNT-1/B MAb (Cotara) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00677716?
This trial is sponsored by Peregrine Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00677716 being conducted?
This trial has 7 study locations across Arizona, Pennsylvania, South Carolina, Kerala. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.